Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: An open-label pilot study

Lupus

Volumn 16, Issue 11, 2007, Pages 896-900

  Tanaka, Hiroshi ^a   Oki, E ^a   Tsugawa, K ^a   Nonaka, K ^a   Suzuki, K ^a   Ito, E ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Adolescents; Maintenance therapy; Single daily dose administration; Systemic lupus erythematosus; Tacrolimus

Indexed keywords

COMPLEMENT COMPONENT C3; PREDNISOLONE; TACROLIMUS;

ADOLESCENT; ADULT; AMENORRHEA; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; INFECTION; KIDNEY BIOPSY; LEUKOPENIA; LIVER DYSFUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MALE; ONSET AGE; PEDIATRICS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; PILOT PROJECTS; TACROLIMUS; TREATMENT OUTCOME;

EID: 36348953163     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307081914     Document Type: Article

References (15)

1. Davidson A, Aranow C. Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol 2006; 18: 468-475.
2. Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000; 136: 243-247.
3. Lai KN, Tang SCW, Mok CC. Treatment for lupus nephritis: a revisit. Nephrology 2005; 10: 180-188.
4. Tanaka H, Tsugawa K, Tsuruga K et al. Mizoribine for the treatment of lupus nephritis in children and adolescents. Clin Nephrol 2004; 62: 412-417.
5. Kondo H, Abe T, Hashimoto H et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J Rheumatol 2004; 31: 243-251.
6. Kawai S, Yamamoto K. Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatology (Oxford) 2006; 45: 441-444.
7. Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005; 68: 813-817.
8. Duddridge M, Powell RJ. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 1997; 56: 690-692.
9. Politt D, Heintz B, Floege J, Mertens PR. Tacrolimus- (FK 506) based immunosuppression in severe systemic lupus erythematosus. Clin Nephrol 2004; 62: 49-53.
10. Maruyama M, Yamasaki Y, Sada K et al. Good response of membranous lupus nephritis to tacrolimus. Clin Nephrol 2006; 65: 276-279.
11. Tse KC, Lam MF, Tang SCW, Tang CSO, Chan TM. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibitor or blockade. Lupus 2007; 16: 46-51.
12. Mosca M, Bencivelli W, Vitali C, Carrai P, Neri R, Bombardieri S. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 2000; 9: 445-450.
13. Davies TH, Ning YM, Sanchez ER. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and immunosuppressive ligand FK506. Biochemistry 2005; 44: 2030-2038.
14. Tanaka H, Tsugawa K, Suzuki K et al. Treatment of difficult cases of systemic-onset juvenile idiopathic arthritis with tacrolimus. Eur J Pediatr 2007; 166: DOI:10.1007/s00431-006-0380-0
15. Tanaka H, Tsugawa K, Suzuki K, Ito E. Renal biopsy findings in children receiving long-term treatment with cyclosporine A given as a single daily dose. Tohoku J Exp Med 2006; 209: 191-196.